#ACR23 Year in Review. Dr Seo did a great job in highlighting key papers. #SLE #Tyk2 Phase 2 RCT of Deucravacitinib recruited pts of diverse ancestry. More pts on DEUC met SRI-4 response vs PBO. Question remains about the inverse/flat dose response. Going to Phase 3 @RheumNow https://t.co/68rYjEnWyN